Navigating the procurement of analytical-grade peptides online requires strict adherence to quality verification, structural validation, and regulatory compliance. KPV (Lysine-Proline-Valine) is a synthesized C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) investigated extensively in preclinical models for its anti-inflammatory properties. PX1 Research provides verified, USA-manufactured KPV to academic and institutional laboratories seeking lot-traceable research compounds.
Navigating the procurement of analytical-grade peptides online requires strict adherence to quality verification, structural validation, and regulatory compliance. KPV (Lysine-Proline-Valine) is a synthesized C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) investigated extensively in preclinical models for its anti-inflammatory properties. PX1 Research provides verified, USA-manufactured KPV to academic and institutional laboratories seeking lot-traceable research compounds.
Sourcing KPV online for laboratory research requires identifying suppliers that provide verified chemical identity, quantitative purity metrics, and strict lot traceability. KPV is a tripeptide sequence (Lys-Pro-Val) derived from the C-terminus of alpha-melanocyte-stimulating hormone (α-MSH), widely studied in preclinical research models for its ability to modulate inflammatory signaling cascades without activating melanocortin receptors.
Researchers seeking to evaluate the KPV peptide must ensure that commercial preparations are free from trifluoroacetic acid (TFA) salts, heavy metals, and bacterial endotoxins. Acquiring research compounds through verified domestic suppliers guarantees that the material has undergone rigorous quality control protocols, including reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) characterization. PX1 Research supplies high-purity research peptides synthesized in ISO 17025 accredited and GMP-compliant facilities to support reproducible experimental outcomes across cell culture and animal models.
KPV is a tripeptide composed of the amino acid sequence L-lysine, L-proline, and L-valine. Synthesized as a structural fragment corresponding to amino acids 11 through 13 of the parent neuropeptide α-MSH, KPV retains the core anti-inflammatory sequence of the larger hormone while lacking the amino acid residues responsible for binding classical melanocortin receptors (MC1R through MC5R). This structural selectivity makes KPV a valuable tool for isolating specific signaling pathways.
The molecular weight of free-base KPV is approximately 342.44 g/mol. In solid-phase peptide synthesis (SPPS), the C-terminal valine residue is anchored to a solid resin support, followed by step-wise coupling of L-proline and L-lysine using protected amino acid derivatives. Due to its short sequence length, KPV exhibits high stability during synthesis; however, ensuring correct stereochemical configuration and eliminating truncated side-products requires advanced chromatographic purification. Investigational literature frequently explores the molecular kinetics of KPV in comparison to broader melanocortin research peptides to delineate pathway-specific downstream effects.
Preclinical investigations demonstrate that KPV exerts its primary biological effects through the intracellular inhibition of nuclear factor kappa B (NF-κB). NF-κB is a master transcriptional regulator responsible for driving the expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. In vitro cell assay models indicate that KPV translocates across the cell membrane to directly interact with nuclear signaling machinery, blocking the translocation of the p65 subunit of NF-κB into the nucleus.
By suppressing NF-κB activation, KPV effectively downregulates the transcription of key pro-inflammatory mediators, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). In vitro data indicate that KPV does not rely on classical membrane-bound melanocortin receptor activation to initiate this response, suggesting a novel, transport-dependent intracellular mechanism of action. Researchers interested in inflammatory pathway dynamics frequently study KPV alongside broader signaling modulators within the PX1 Research library.
A primary focus of KPV literature centers on its application in models of gastrointestinal inflammation and mucosal barrier maintenance. In rodent models of dextran sulfate sodium (DSS)-induced colitis, administration of KPV has been shown to reduce histological damage, decrease mucosal myeloperoxidase (MPO) activity, and preserve epithelial tight junction architecture. These findings suggest that KPV plays a functional role in mitigating luminal inflammatory cascades.
In vitro assays utilizing Caco-2 cell monolayers demonstrate that KPV uptake is mediated in part by the intestinal peptide transporter 1 (PepT1). Under inflammatory conditions, PepT1 expression is frequently upregulated on enterocytes, facilitating increased intracellular accumulation of KPV. Once inside the cell, KPV attenuates cytokine-induced epithelial permeability by maintaining the expression and localization of tight junction proteins such as zonula occludens-1 (ZO-1) and occludin. Consequently, KPV remains a key candidate compound in research evaluating inflammatory bowel disease mechanics and mucosal healing.
When designing preclinical experiments focused on mucosal repair and barrier restoration, investigators often compare KPV with other established tissue-protective research peptides. While KPV functions primarily via direct intracellular suppression of NF-κB and PepT1-mediated transport, BPC-157 acts through the upregulation of growth factor pathways, nitric oxide synthesis, and VEGFR2 activation to promote angiogenesis and tissue granulation. In contrast, larazotide acetate functions specifically as a tight junction regulator by antagonizing zonulin signaling to prevent intestinal hyperpermeability.
Understanding these mechanistic distinctions allows laboratories to select the appropriate compound or combination protocol for target assays. While larazotide targets intercellular junction opening and BPC-157 accelerates vascularized repair, KPV provides targeted suppression of upstream pro-inflammatory transcription factors within epithelial and immune cell lines. Laboratories interested in comparative inflammation modeling can explore these targets through wholesale research procurement channels to support high-throughput screening.
Because peptide synthesis can generate deletion sequences, diastereomers, and residual chemical reagents, verifying supplier quality is paramount when procuring KPV online. Reputable vendors must provide transparent, lot-specific documentation that proves chemical identity, purity, and safety from biological contaminants. Researchers should avoid sources that rely on generalized, static analytical certificates or fail to disclose facility compliance standards.
PX1 Research enforces a strict quality assurance protocol for every batch of KPV distributed. Every lot manufactured in our domestic US facilities undergoes independent validation by accredited testing bodies. These checks verify that the peptide sequence matches specifications precisely and that residual solvents, counterions, and synthesis reagents fall well below acceptable analytical thresholds.
Analytical verification of KPV relies on two primary orthogonal techniques: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). RP-HPLC quantifies the chemical purity of the sample by separating the target tripeptide from synthesis artifacts, ensuring a minimum purity threshold of 98% to 99%. Mass spectrometry confirms the exact molecular weight and isotopic distribution of the Lys-Pro-Val sequence.
In addition to structural and purity testing, quantitative endotoxin testing via the Limulus Amebocyte Lysate (LAL) assay is critical for cell culture and preclinical applications. Bacterial endotoxins (lipopolysaccharides) can artifactually activate Toll-like receptor 4 (TLR4) and NF-κB pathways in cell cultures, completely invalidating experimental data regarding KPV's anti-inflammatory properties. PX1 Research mandates third-party endotoxin testing per lot, ensuring limits meet stringent laboratory research requirements.
KPV is supplied as a lyophilized (freeze-dried) cake or powder, typically stabilized as an acetate salt. To maintain the integrity of the peptide during laboratory reconstitution, researchers should handle the vial under sterile conditions within a certified laminar flow hood. Lyophilized KPV exhibits high solubility in aqueous solutions due to its hydrophilic lysine residue and short sequence length.
For standard in vitro and in vivo assays, lyophilized KPV should be reconstituted using sterile, endotoxin-free water or phosphate-buffered saline (PBS, pH 7.4). Gentle manual rotation of the vial is recommended to facilitate dissolution; vortexing or vigorous agitation should be avoided to prevent mechanical shearing or aggregation. If long-term stock solutions are required, reconstituting in sterile buffer, aliquoting into single-use polypropylene tubes, and storing at -80°C minimizes freeze-thaw degradation cycles.
Lyophilized KPV demonstrates excellent long-term stability when stored at controlled temperatures. Upon receipt, sealed vials containing freeze-dried peptide should be stored at -20°C or -80°C in a desiccated environment protected from light exposure. Under these conditions, the lyophilized peptide remains stable for up to 24 months without significant chemical degradation or hydrolysis.
Once reconstituted into aqueous solution, KPV exhibits moderate stability at 4°C for short-term experimental periods (up to 7–14 days). However, for extended study timelines, stock solutions should be rapidly frozen and maintained at -80°C. Researchers must avoid repeated freeze-thaw cycles, as cyclic phase transitions induce peptide precipitation and concentration variance. Environmental exposure to atmospheric humidity should be minimized by allowing refrigerated vials to reach room temperature before opening.
When purchasing KPV online, partnering with a domestic supplier that specializes exclusively in laboratory-grade research compounds ensures batch-to-batch consistency and supply chain security. PX1 Research operates state-of-the-art manufacturing and distribution centers located in California and Arizona, providing immediate dispatch and rapid domestic delivery to research institutions nationwide.
All orders placed before standard daily cutoffs ship same-day (Monday through Friday). By maintaining direct oversight of synthesis, analytical validation, packaging, and logistics, PX1 Research eliminates the risk of third-party degradation or compromised chain-of-custody. Qualified researchers can browse our full catalog of anti-inflammatory peptides to equip their laboratories with fully verified compounds.
What is KPV and what is its chemical structure?
KPV is a tripeptide consisting of L-lysine, L-proline, and L-valine (Lys-Pro-Val). It represents the C-terminal amino acid sequence (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH) and is studied in research settings for its anti-inflammatory mechanism.
How does KPV differ from full-length α-MSH in preclinical research?
While full-length α-MSH binds to melanocortin receptors (MC1R–MC5R) to induce melanogenesis and systemic endocrine effects, the KPV tripeptide fragment does not activate classical melanocortin receptors. Instead, KPV acts primarily via intracellular pathways and PepT1 transporter uptake to suppress NF-κB nuclear translocation.
What purity levels are required for purchasing KPV online for laboratory use?
For rigorous in vitro and preclinical research, KPV should possess a chemical purity of ≥98% as measured by RP-HPLC. Additionally, mass spectrometry validation must confirm the molecular weight (342.44 g/mol), and endotoxin testing should confirm levels appropriate for sensitive cellular assays.
How should lyophilized KPV be stored upon delivery?
Lyophilized KPV should be stored at -20°C or -80°C in a dry, dark environment upon arrival. Under sub-zero desiccated storage, the freeze-dried peptide remains stable for up to 24 months.
What solvents are recommended for reconstituting KPV in the lab?
KPV is readily soluble in aqueous media. It is typically reconstituted using sterile, endotoxin-free water or sterile phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear mechanical agitation during dissolution.
Why is endotoxin testing critical when sourcing KPV online?
Bacterial endotoxins (LPS) trigger inflammatory signals through TLR4 pathways in cell culture and animal models. If a KPV sample is contaminated with endotoxins, it can artifactually mask or distort the peptide's true anti-inflammatory research outcomes.
Where does PX1 Research manufacture and ship KPV?
PX1 Research manufactures its compounds in USA-based, ISO 17025 accredited and GMP-compliant facilities. Orders are fulfilled directly from domestic distribution centers in California and Arizona, offering same-day shipping Monday through Friday.
Is KPV provided by PX1 Research suitable for human clinical use?
No. All compounds supplied by PX1 Research, including KPV, are intended strictly for in vitro laboratory research and preclinical animal experimentation. They are explicitly not for human or veterinary medical use, clinical trial, or therapeutic application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.